Kim Schenk is speaking on two panels during this conference, “Patent Valuation Versus Patent Damages: Is There/Should There Be a Difference?” and “What’s New in Patent Damages.” This conference is for corporate counsel, intellectual property litigators, and those involved in the ever-changing patent environment
For more information, click here.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...